AstraZeneca and Alexion’s gefurulimab (Klygefa) cleared a key FDA hurdle for generalized myasthenia gravis, adding another once-weekly option for anti-AChR antibody–positive patients in a crowded treatment segment. The approval also underscores continued momentum for self-administered biologics that shift administration models from clinic to home settings. On the oncology economics front, a UK-focused model found tisotumab vedotin to be cost-effective for recurrent or metastatic cervical cancer, while the same analysis concluded it was not cost-effective in China. The divergence was driven by higher modeled costs relative to chemotherapy and different willingness-to-pay thresholds, illustrating how market access decisions may vary sharply by geography. Together, the two developments highlight how biotech outcomes increasingly hinge not only on clinical performance but also on how regulators and payers contextualize value across endpoints, patient segments, and national health technology assessment frameworks.